The OCMX™ is pleased to announce the listing of Adcura to its online portal which offers financial networks the ability to learn more about this exciting opportunity.

EDEN PRAIRIE, MN, February 09, 2022 /24-7PressRelease/ — Adcura gets listed on THE OCMX™

Adcura, Inc. is a multi-stage medical technology company focused on the application of science and engineering directed towards the design specification and development of first-to-market proprietary solutions that aim to bring differentiated clinical and surgical benefits to unaddressed needs for those suffering from spine related diseases and disorders.

In addition to early stage research and development activities, the company is responsible for carrying-out commercialization efforts for its differentiated surgical solution product offerings required to reach the market, as well as assuming manufacturing responsibilities of its proprietary products. Adcura also markets and distributes is surgical solution offerings to its surgeon end users.

The OCMX™ is pleased to announce the listing of Adcura to its online portal which offers financial networks the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on Adcura and concluded that there is indeed a tremendous potential for this company.

The OCMX™ noted that Adcura exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

Adcura is driven towards the pursuit of progressing the current standard of care offered within spinal surgery and treatment to a new level of advancement. Focused on producing highly differentiated, first-to-market technologies, and surgical techniques that together offer a new generation of precision for producing true Patient-Specific Results.

These proprietary surgical solution offerings remain the MARKETS-ONLY fully adjustable implantable technologies with validated, techniques, achieving clinical and surgical results that are patient-specific, surgicaly efficient, minimally invasive, intuitive, and economical on an unmatched level.

Further inspired by innovation targeted towards artificial intelligence and machine learning, Adcura’s high-precision surgical solution offerings lend a unique technology with a foundation adaptable towards the future of autonomous and robotic based surgery.


Within the next 12-18 Months:
• Full U.S. commercialization launch and execution efforts of the flagship product system Sagittae® leading to double digit growth rate quarter-over-quarter each quarter with an estimated active user base of 30+ surgeons
• New Technology and Surgical Solution Development and Commercialization Launches: Achieving efforts towards the launch of 2-3 new technology and surgical solution product system offerings leading to a first-to-market precise patient-specific technology and surgical solution platform in the marketplace
• Initial commercialization and ramp-up in the Middle East and Latin America Foreign Market World Areas in addition to the U.S. Market

Within the next 24+ Months:
• 100+ active surgeon users within the greater spinal device market
• Global commercialization in 2-3 large foreign marketplaces in addition to the U.S. Market
Further technology and commercialization efforts that focus on first-to-market patient-specific solutions that are adaptable and integratable towards the future direction of autonomous and robotic surgical systems.


Sagittae® (flagship product line) Adjustable Expandable Technology: Addressing multiple clinical and surgical problems present within lumbar spine procedures current standard of care
1. Patient-Specific
2. Maximize Surgical Efficiencies
3. Minimize Patient Post-Operative Complications
4. Streamline Inventory

The company is approaching the successful implantation of its 100th device with multiple surgeon users across the continental U.S. Further, all implanted devices have produced positive operative and initial post-operative results and over 1/3rd of the patient population receiving the Sagittae® implant technology is approaching 3-years since implantation with successful long-term post-operative results.


Eric Blossey, CEO/President/Chairman of the Board: Key founding member and previously company’s Chief Commercial officer. Architect behind the commercialization plan and strategy for the company. Over a decade of experience holding key sales and sales leadership roles for small, mid, and large size companies within industry. Critical member of recent company fundraising success and rebranding imitative and efforts. Currently driving the company’s strategic vision and imitative efforts.

Andrew Rogers, COO/Director: Key founding member and one of the two inventors behind the company’s unique and proprietary technology. Head of product design and development, product launch, and regulatory affairs and quality assurance initiatives for multiple design iterations and commercialized generations of the flagship product line Sagittae®. Inventor on 10 granted patents and 31 additional pending patents. Critical member of recent company fundraising success and rebranding imitative and efforts. Currently head of engineering and design, manufacturing and operations, as well as quality assurance and regulatory affairs efforts.

James D. Smith III, M.D., Key Opinion Leader (KOL)/Director: Key founding member and original inceptor of the company’s proprietary technology. 1st initial angel investor during technology incubation phase of company. Serves as the main Key Opinion (KOL) for the company’s orthopedic surgeon customer base, along with assisting in new product design and development early phases input. Current licensed and trained Spine Surgeon at Gadsden Orthopedics with nearly two decades of experience of practice, along with 15+ years of teaching and lecturing on spinal fusion techniques.

The OCMX™ , established in 2009, is a next generation investor relations and marketing outreach firm. Through our online Ocmx portal, we connect companies with financial networks, generating interest and awareness for their opportunity.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here